Adellgene® Friedreich’s Ataxia

Kit for the determination of the GAA triplet repeats number of the FXN gene by fluorescent fragment analysis.

Information about the product

Friedreich’s ataxia (FRDA) is the most common hereditary ataxia and it´s an autosomal recessive degenerative disease.

The most common DNA abnormality associated with Friedreich’s ataxia (FRDA) is the expansion of a GAA triplet repeat polymorphism localized in the first intron of the gene encoding frataxin (FXN). Pathogenic GAA expansion alleles are in the size range of 50 to >1300 repeats with three different intervals:

  • healthy (between 5-30 repeats),
  • Mild symptoms (30-49 repeats)
  • Severe symptoms (50-1300 repeats)

Intended Use

Adellgene® Friedreich’s Ataxia is a semi-automated in vitro diagnostic kit designed for use in clinical laboratories which quantitatively determines the number of repetitions of GAA (guanine-adenine-adenine) in the first intron of the gene encoding frataxin (FXN) located in chromosome 9 resulting in Frie­dreich’s ataxia disease. It aims to aid diagnosis associated with clinical findings in Friedreich’s ataxia that span from mild to severe symptoms.

The use of this kit is the determination of healthy alleles who have between 5 to 30 GAA repeats, patients with mild phenotype (30-49 repeats), and severe (50-1300).

The technology is based on the polymerase chain reaction (PCR) of genomic DNA extracted from peripheral blood followed by fluorescence analysis of the size of the PCR fragments obtained by genetic analyser and conversion of that size in the number of GAA repeats.

Patients who can benefit from this determination are those referred by a specialist. The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the instructions for use.

Workflow

workflow adellgene

Results

Adellgene Friedreich s Ataxia Reaction 1 healthy allele 15R
Adellgene Friedreich s Ataxia Reaction 2 mutated allele more than 200R
Adellgene Friedreich s Ataxia title
Adellgene® Friedreich’s Ataxia 5

Limitations

  • Mutations (point mutations, insertions, deletions) at amplification primer sites are possible and may result in the lack of allele definition. Other technologies could be necessary to resolve the genotyping.
  • Data and result interpretation should be revised by qualified personnel.

Area:

Molecular Genetics, Neurology, Targeted study of specific pathologies

Technology:

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

The SeqOne Genomic Analysis Platform

SeqOne is an in vitro diagnostic platform for genetic analysis, designed to help healthcare professionals interpret next-generation sequencing (NGS) and array CGH data. The platform provides qualitative and actionable results, functioning as a clinical decision support system. Key features It is an in vitro diagnostic medical device, Class C with CE-IVD marking and certified according…
SeqOne
Next Generation Sequencing (NGS)

Devyser FH

Next-generation sequencing kit for the comprehensive analysis of genes associated with familial hypercholesterolemia, including a polygenic risk score and a SNP panel for statin response. Detailed Description Operating Principle The Devyser FH kit is an amplicon-based NGS library preparation solution with a single-tube protocol that enables targeted amplification and sample indexing within a streamlined workflow.…
Devyser
Next Generation Sequencing (NGS)

Illumina DNA Prep with Exome 2.5 Enrichment

Comprehensive solution for whole exome sequencing with Illumina technology, combining library preparation by tagmentation with capture-based enrichment, sequencing, and bioinformatics analysis, enabling a single workflow. Detailed Description Operating Principle The workflow uses magnetic bead-linked transposomes (eBLT) for rapid and uniform tagmentation. Following index PCR, a hybrid capture enrichment step is performed using the Twist Bioscience…
Illumina
Next Generation Sequencing (NGS)

Devyser CFTR for NGS

Operating Principle: The Devyser CFTR NGS kit redefines the genetic diagnosis of cystic fibrosis by offering a comprehensive and precise solution, validated for clinical use. With a unique single-tube library preparation approach, this kit optimizes the CFTR gene analysis process, significantly reducing hands-on time and contamination risk while improving diagnostic accuracy. Clinical Applications Advances in…
Devyser
Next Generation Sequencing (NGS)